1. Achieving serum urate targets within 1 year of treatment initiation in gout patients may significantly reduce major cardiovascular events.
2. Patients who achieved target serum urate levels demonstrated a higher 5-year MACE-free survival rate and a lower risk of MACE.
3. Two investigational URAT1 inhibitors demonstrated superior efficacy and favorable safety profiles compared with standard allopurinol therapy.
4. Pozdeutinurad (AR882) showed potential as a safe treatment option for gout patients.
5. Ruzinurad demonstrated superior urate-lowering efficacy and well-tolerated safety profile compared with allopurinol.

Source: EULAR Press Release